文献速递慢性肾脏病

2型糖尿病患者尿色氨酸-犬尿氨酸通路代谢物与CKD进展风险

Urinary Metabolites in Tryptophan-Kynurenine Pathway and Risk of CKD Progression in Patients With Type 2 Diabetes.
PubMed 文献 · Am J Kidney Dis · 2026-10-20

前瞻性队列研究纳入1892例东南亚2型糖尿病患者,并在951例CRIC糖尿病参与者中验证。中位随访7.2年发生224例CKD进展事件;尿犬尿氨酸、3-羟基犬尿氨酸、犬尿喹啉酸及KTR每升高1个SD与CKD进展风险升高相关。

要点

  • 尿犬尿氨酸通路代谢物升高与2型糖尿病患者CKD进展风险独立相关。
  • 基线eGFR<60者中上述关联更明显。
  • CRIC队列中尿色氨酸和犬尿氨酸亦与CKD进展风险相关。

核心结论

  • 2型糖尿病患者尿色氨酸-犬尿氨酸通路代谢物浓度较高与CKD进展风险较高相关。

研究设计与样本

  • 前瞻性队列研究;主要分析纳入1892例东南亚2型糖尿病患者,验证研究纳入951例基线有糖尿病的CRIC参与者。

主要发现

  • 中位随访7.2年共发生224例CKD进展事件。
  • 校正已知临床危险因素后,尿犬尿氨酸每升高1个SD,CKD进展风险高1.60倍(95%CI 1.16-2.22)。
  • 尿3-羟基犬尿氨酸每升高1个SD,CKD进展风险高1.64倍(95%CI 1.17-2.31)。
  • 尿犬尿喹啉酸每升高1个SD,CKD进展风险高1.47倍(95%CI 1.10-1.97);KTR每升高1个SD风险高1.97倍(95%CI 1.43-2.71)。
  • CRIC糖尿病参与者中,尿色氨酸和犬尿氨酸每升高1个SD分别与CKD进展风险高1.60倍(95%CI 1.24-2.06)和1.35倍(95%CI 1.05-1.73)独立相关。

关键数值与推荐

  • CKD进展定义为复合终点:新发终末期肾病(持续eGFR<15 ml/min/1.73m2、维持性透析或肾脏死亡)或血清肌酐浓度翻倍。

临床怎么用

  • 在2型糖尿病患者中,可关注尿色氨酸-犬尿氨酸通路代谢物以辅助CKD进展风险分层。

局限性

  • 观察性研究,存在未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Tryptophan-kynurenine pathway is integral for energy metabolism and immune-inflammation regulation. We sought to study the associations between urinary metabolites in tryptophan-kynurenine pathway and risk of chronic kidney disease (CKD) progression in patients with type 2 diabetes. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 1,892 participants with type 2 diabetes from Southeast Asia were included in the primary analysis; 951 Chronic Renal Insufficiency Cohort (CRIC) participants with diabetes at baseline were included in the validation study. EXPOSURES: Urinary tryptophan, kynurenine, 3-hydroxykynurenine, kynurenic acid, xanthurenic acid and kynurenine-to-tryptophan ratio (KTR). OUTCOMES: CKD progression defined as a composite of incident end stage kidney disease (sustained eGFR < 15 ml/min/1.73m2, maintenance dialysis, renal death) or doubling of serum creatinine concentration. ANALYTICAL APPROACH: Cause-specific hazard regression. RESULTS: A total of 224 CKD progression events were identified over a median follow-up of 7.2 years. Each one SD increase in the concentration of urinary kynurenine, 3-hydroxykynurenine, kynurenic acid, and KTR was associated with 1.60 [95% CI 1.16-2.22], 1.64 [1.17-2.31], 1.47 [1.10-1.97] and 1.97 [1.43-2.71] fold higher risk of CKD progression, respectively, after adjustment for known clinical risk factors. These associations were more pronounced in participants with prevalent CKD (eGFR <60 ml/min/1.73m2) compared to those with preserved eGFR. Each one SD increase in urinary tryptophan and kynurenine concentrations was independently associated with 1.60 [1.24-2.06] and 1.35 [1.05-1.73] fold higher risk of CKD progression, respectively, in CRIC participants with diabetes. LIMITATIONS: Observational study with unmeasured confounding. CONCLUSIONS: Higher concentrations of urinary metabolites in the tryptophan-kynurenine pathway were associated with higher risk of CKD progression in patients with type 2 diabetes. Future studies are warranted to elucidate the biological mechanisms linking the tryptophan-kynurenine pathway and progression of kidney disease.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Liu JJ, Liu S, Zheng H, et al. Urinary Metabolites in Tryptophan-Kynurenine Pathway and Risk of CKD Progression in Patients With Type 2 Diabetes. Am J Kidney Dis. 2026. PMID: 42901298. doi:10.1053/j.ajkd.2026.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。